Zobrazeno 1 - 10 of 13 pro vyhledávání: '"Mary S. Holubasch"'
1
Akademický článek
PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology
Autor: Stephanie M. Eastwood, Matthew R. Meyer, Kristopher M. Kirmess, Traci L. Wente-Roth, Faith Irvin, Mary S. Holubasch, Philip B. Verghese, Tim West, Joel B. Braunstein, Kevin E. Yarasheski, John H. Contois
Publikováno v: Diagnostics, Vol 14, Iss 16, p 1739 (2024)
Alzheimer’s disease (AD) is a progressive irreversible neurodegenerative disorder that represents a major global public health concern. Traditionally, AD is diagnosed using cerebrospinal fluid biomarker analysis or brain imaging modalities. Recentl
Externí odkaz: https://doaj.org/article/28e6fa8ca16042328d46beeee1e30200
Zobrazit plný text záznamu
2
Akademický článek
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis
Autor: Tim West, Kristopher M. Kirmess, Matthew R. Meyer, Mary S. Holubasch, Stephanie S. Knapik, Yan Hu, John H. Contois, Erin N. Jackson, Scott E. Harpstrite, Randall J. Bateman, David M. Holtzman, Philip B. Verghese, Ilana Fogelman, Joel B. Braunstein, Kevin E. Yarasheski
Publikováno v: Molecular Neurodegeneration, Vol 16, Iss 1, Pp 1-12 (2021)
Abstract Background The development of blood-based biomarker tests that are accurate and robust for Alzheimer’s disease (AD) pathology have the potential to aid clinical diagnosis and facilitate enrollment in AD drug trials. We developed a high-res
Externí odkaz: https://doaj.org/article/c91cadfca9d9471da9fe34743049c0b5
Zobrazit plný text záznamu
10
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis
Autor: Kevin E. Yarasheski, Kristopher M. Kirmess, Tim West, John H. Contois, Erin Jackson, David M. Holtzman, Mary S. Holubasch, Ilana Fogelman, Philip B. Verghese, Scott E. Harpstrite, Joel B. Braunstein, Stephanie S. Knapik, Yan Hu, Matthew R. Meyer, Randall J. Bateman
Publikováno v: Molecular Neurodegeneration, Vol 16, Iss 1, Pp 1-12 (2021)
Molecular Neurodegeneration
Background The development of blood-based biomarker tests that are accurate and robust for Alzheimer’s disease (AD) pathology have the potential to aid clinical diagnosis and facilitate enrollment in AD drug trials. We developed a high-resolution m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6b0b819c957f92834be4448cdfe1f41
https://doi.org/10.1186/s13024-021-00451-6
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje